Capricor Therapeutics, Inc.
CAPR
$30.24
-$0.66-2.14%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
3/18/2026
-
Insider Monkey
3/17/2026
-
Insider Monkey
3/16/2026
-
MarketBeat
3/15/2026
-
Simply Wall St
3/14/2026
-
Ticker Report
3/14/2026
-
Tickeron - Stocks
3/14/2026
-
Simply Wall St
3/14/2026
-
TipRanks Financial Blog
Capricor Therapeutics, Inc. (CAPR) Presents at 2026 MDA Clinical & Scientific Conference - Slideshow
3/13/2026
-
SeekingAlpha
3/13/2026
-
TipRanks Financial Blog
3/13/2026
-
MarketBeat
3/13/2026
-
Benzinga
3/13/2026
-
Ticker Report
3/13/2026
-
MarketBeat
3/13/2026
-
MarketBeat
3/13/2026
-
TipRanks Financial Blog
3/13/2026
-
TipRanks Financial Blog
3/13/2026
-
MarketBeat
3/13/2026
-
SeekingAlpha
3/13/2026
-
Seeking Alpha: Transcripts
3/12/2026
-
MarketBeat
3/12/2026
-
MarketBeat
3/12/2026
-
Globe Newswire
3/12/2026
-
TipRanks Financial Blog
3/12/2026
-
Simply Wall St
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Tuesday, March 17, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 11 and 15 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
858 727 1755
Address
10865 Road to the Cure
San Diego, CA 92121
San Diego, CA 92121
Country
Year Founded
Business Description
Sector
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy...
more